Management of Corneal Neovascularization With Diathermy and Intrastromal Bevacizumab Injection.

IF 2 4区医学 Q2 OPHTHALMOLOGY

Eye & Contact Lens-Science and Clinical Practice Pub Date : 2025-05-28 DOI:10.1097/ICL.0000000000001189

Gideon Nkrumah, Alex Mammen, Vishal Jhanji

{"title":"Management of Corneal Neovascularization With Diathermy and Intrastromal Bevacizumab Injection.","authors":"Gideon Nkrumah, Alex Mammen, Vishal Jhanji","doi":"10.1097/ICL.0000000000001189","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the outcomes of patients with corneal neovascularization treated with intrastromal injection of bevacizumab and corneal fine needle diathermy (FND).Methods: This is a retrospective case series of six patients with at least 6 months follow-up after intrastromal injection of bevacizumab and FND. The main outcome measures include change in best-corrected visual acuity (BCVA) and regression of corneal neovascularization at follow-up. Slitlamp photographs were taken pre and post procedure.Results: The mean age of the patients was 64.2 years, and the baseline BCVA ranged from 20/40 to 20/100. At postoperative months 1 and 6, all patients had improvement in corneal neovascularization, with 67% (4/6) showing total resolution while 33% (2/3) had residual deep fine vessels. Best-corrected visual acuity improved in two patients and remained stable in four patients. Two patients had improvement in lipid keratopathy at 6 months.Conclusions: Combined intrastromal injection of bevacizumab and FND is an effective treatment for corneal neovascularization.","PeriodicalId":50457,"journal":{"name":"Eye & Contact Lens-Science and Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye & Contact Lens-Science and Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICL.0000000000001189","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the outcomes of patients with corneal neovascularization treated with intrastromal injection of bevacizumab and corneal fine needle diathermy (FND).

Methods: This is a retrospective case series of six patients with at least 6 months follow-up after intrastromal injection of bevacizumab and FND. The main outcome measures include change in best-corrected visual acuity (BCVA) and regression of corneal neovascularization at follow-up. Slitlamp photographs were taken pre and post procedure.

Results: The mean age of the patients was 64.2 years, and the baseline BCVA ranged from 20/40 to 20/100. At postoperative months 1 and 6, all patients had improvement in corneal neovascularization, with 67% (4/6) showing total resolution while 33% (2/3) had residual deep fine vessels. Best-corrected visual acuity improved in two patients and remained stable in four patients. Two patients had improvement in lipid keratopathy at 6 months.

Conclusions: Combined intrastromal injection of bevacizumab and FND is an effective treatment for corneal neovascularization.

查看原文本刊更多论文

透热联合基质内注射贝伐单抗治疗角膜新生血管。

目的：评价贝伐单抗基质内注射联合角膜细针透热（FND）治疗角膜新生血管的疗效。方法：这是一个回顾性的病例系列，6例患者在骨髓内注射贝伐单抗和FND后至少6个月的随访。主要观察指标包括最佳矫正视力（BCVA）的变化和随访时角膜新生血管的消退。手术前后分别拍摄裂隙灯照片。结果：患者平均年龄为64.2岁，基线BCVA范围为20/40 ~ 20/100。术后第1、6个月，所有患者的角膜新生血管均有改善，67%（4/6）患者的角膜新生血管完全消退，33%（2/3）患者的角膜深细血管残留。两名患者的最佳矫正视力改善，四名患者保持稳定。2例患者在6个月时脂质角膜病变得到改善。结论：贝伐单抗联合FND是治疗角膜新生血管形成的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Eye & Contact Lens-Science and Clinical Practice OPHTHALMOLOGY-

CiteScore

4.50

自引率

4.30%

发文量

150

审稿时长

6-12 weeks

期刊介绍： Eye & Contact Lens: Science and Clinical Practice is the official journal of the Contact Lens Association of Ophthalmologists (CLAO), an international educational association for anterior segment research and clinical practice of interest to ophthalmologists, optometrists, and other vision care providers and researchers. Focusing especially on contact lenses, it also covers dry eye disease, MGD, infections, toxicity of drops and contact lens care solutions, topography, cornea surgery and post-operative care, optics, refractive surgery and corneal stability (eg, UV cross-linking). Peer-reviewed and published six times annually, it is a highly respected scientific journal in its field.